PND2 SAFETY AND IMMUNOGENICITY OF REBIF® NEW FORMULATION (RNF) A NEW SUBCUTANEOUS FORMULATION OF INTERFERON BETA-1A 44 MCG THREE TIMES WEEKLY- 1-YEAR RESULTS OF A PHASE IIIB STUDY IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
May 1, 2007, 00:00
10.1016/S1098-3015(10)68801-8
https://www.valueinhealthjournal.com/article/S1098-3015(10)68801-8/fulltext
Title :
PND2 SAFETY AND IMMUNOGENICITY OF REBIF® NEW FORMULATION (RNF) A NEW SUBCUTANEOUS FORMULATION OF INTERFERON BETA-1A 44 MCG THREE TIMES WEEKLY- 1-YEAR RESULTS OF A PHASE IIIB STUDY IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)68801-8&doi=10.1016/S1098-3015(10)68801-8
First page :
Section Title :
Open access? :
No
Section Order :
589